G-CON Manufacturing and Ori Biotech Collaborate to Develop an Integrated Modular Manufacturing Platform for Cell and Gene Therapy Developers
Summary
“G-CON is a leader in flexible cell and gene therapy manufacturing and, with this collaboration, Ori continues to partner with best-in-class, expert suppliers across the CGT ecosystem. This partnership will help enable our vision for a fully integrated, automated, closed system manufacturing platform supporting the cell and gene therapy industry,” said Farlan Veraitch, Co-Founder and CSO, Ori Biotech. “Enhancing automation and closing the process really eliminates a lot of the high cost elements and manual interventions currently required in making cell therapies. The promise of the full stack Ori platform is to fully automate CGT manufacturing to increase throughput, improve quality and decrease costs by combining hardware, software and data services. Ori was founded by Professor Chris Mason (AVRO) and Dr. Farlan Veraitch (UCL) and has brought together a seasoned Board and executive management team with over 100 years of pharmaceutical, CGT and venture building experience including CEO Jason C. Foster (Indivior), CBO Jason Jones (Miltenyi Biotec), VP Tom Heathman (HCATS) alongside expert advisers like Bruce Levine, Anthony Davies and Bob Preti.